NICE consults on ninth work wave
The National Institute for Clinical Excellence is consulting on a ninth wave of technology appraisals.
The topics proposed are adefovir dipivoxil (Hepsera) for chronic hepatitis
B, atrasentan for prostate cancer, cetuximab (Erbitux) for head and neck
cancer,
erythropoetin (Eprex/NeoRecormon) for chemotherapy-induced anaemia, etanercept
(Enbrel) and infliximab (Remicade) for ankylosing spondylitis, inhaled
insulins, melagatran and ximelagatran (Exanta) for (a) treatment of venous
thromboembolism and (b) prevention of stroke after atrial
fibrillation, natalizumab (Antegren) for multiple sclerosis, nesiritide
(Natrecor) for acute decompensated heart failure, pegaptanib (Macugen)
for age-related macular degeneration, prasterone (dehydroepiandrosterone,
DHEA) for systemic lupus erythematosus, thrombophilia screening in patients
at risk of deep vein thrombosis, clinics for assessing and preventing
falls, and HealOzone for tooth decay.
Comments on the proposed programme can be sent to Catriona Gregory (tel
0113 254 5636, e-mail catriona.gregory@doh.gsi.gov.uk) by 5 September.
|
